W K Kang
Overview
Explore the profile of W K Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jo H, Lee M, Lee Y, Kim H, Hong J, Lee J, et al.
Clin Oncol (R Coll Radiol)
. 2022 Mar;
34(8):e323-e328.
PMID: 35248464
Aim: To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. Materials And...
2.
Park S, Lim D, Sohn T, Lee J, Zang D, Kim S, et al.
Ann Oncol
. 2020 Dec;
32(3):368-374.
PMID: 33278599
Background: Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens...
3.
Angell H, Lee J, Kim K, Kim K, Kim S, Park S, et al.
Oncoimmunology
. 2019 Feb;
8(2):e1544442.
PMID: 30729066
This study investigates the association of PD-L1 expression and immune cell infiltrates and their impact on clinical outcome, in addition to their overlap with microsatellite instability (MSI), HER2 and ATM...
4.
Sundar R, Huang K, Qamra A, Kim K, Kim S, Kang W, et al.
Ann Oncol
. 2019 Jan;
30(3):424-430.
PMID: 30624548
Background: Utilization of alternative transcription start sites through alterations in epigenetic promoter regions causes reduced expression of immunogenic N-terminal peptides, which may facilitate immune evasion in early gastric cancer. We...
5.
Boku N, Ryu M, Kato K, Chung H, Minashi K, Lee K, et al.
Ann Oncol
. 2018 Dec;
30(2):250-258.
PMID: 30566590
Background: Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy of...
6.
Kim S, Banks K, Pectasides E, Kim S, Lanman R, Talasaz A, et al.
Ann Oncol
. 2018 Feb;
29(4):1037-1048.
PMID: 29409051
Background: To identify predictive markers for responders in lapatinib-treated patients and to demonstrate molecular changes during lapatinib treatment via cell-free genomics. Patients And Methods: We prospectively evaluated the efficacy of...
7.
Kim J, Kim K, Kim S, Lee J, Park S, Park J, et al.
J Cancer
. 2017 Aug;
8(12):2263-2268.
PMID: 28819429
The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors in metastatic colorectal cancer (CRC) and has also been reported to...
8.
Kim S, Kim S, Klempner S, Yoon J, Kim N, Ahn S, et al.
Ann Oncol
. 2016 Dec;
28(3):547-554.
PMID: 28028034
Background: Targeting oncogenic genomic aberrations is an established therapeutic strategy in multiple tumor types. Molecular classification has uncovered a number of novel targets, and rapamycin-insensitive companion of mTOR (RICTOR) amplification...
9.
Lee J, Kim D, Ahn Y, Lim D, Huh S, Shin S, et al.
Cancer Res Treat
. 2015 Dec;
33(5):398-403.
PMID: 26680814
Purpose: This study was performed in order to evaluate the effectiveness of combined chemotherapy and radiotherapy (RT) in primary central nervous system lymphoma (PCNSL). Materials And Methods: From January 1995...
10.
Lee W, Lee K, Kim K, Ryoo B, Kim W, Kang W, et al.
Cancer Res Treat
. 2015 Dec;
33(3):225-8.
PMID: 26680789
Purpose: To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanced colorectal cancer. Materials And Methods: Forty-three patients with advanced, bidimensionally...